10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x     QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended February 29, 2012

¨     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 000-53446

ABSOLUTE LIFE SOLUTIONS, INC.

(Exact name of registrant as specified in its charter)

Nevada	71-1013330
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
45 Broadway, 6th Floor
New York, New York	10006
(Address of principal executive offices)	(Zip Code)
(212) 201-4070
(Registrant's telephone number, including area code)

__________________________________________

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x  No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	£	Accelerated filer	£
Non-accelerated filer	¨ (Do not check if a smaller reporting company)	Smaller reporting company	x.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No x

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. 88,625,690 shares of common stock as of April 18, 2012.

ABSOLUTE LIFE SOLUTIONS, INC.

Quarterly Report On Form 10-Q

For The Quarterly Period Ended

February 29, 2012

INDEX

			Page
PART I - FINANCIAL INFORMATION
	Item 1.	Condensed Financial Statements	3
	Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	17
	Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22
	Item 4.	Controls and Procedures	22
PART II - OTHER INFORMATION
	Item 1.	Legal Proceedings	23
	Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	23
	Item 3.	Defaults Upon Senior Securities	23
	Item 5.	Other Information	23
	Item 6.	Exhibits	23

2

Item 1. Financial Statements

The following unaudited interim condensed financial statements of Absolute Life Solutions, Inc. (sometimes referred to as "we", "us" or "our Company") are included in this quarterly report on Form 10-Q:

	Page
Condensed Balance Sheets at February 29, 2012 (unaudited) and August 31, 2011	4
Condensed Statements of Operations for the three months and six months  ended February 29, 2012 and February 28, 2011 (unaudited)	5
Condensed Statements of Cash Flows for the six months ended February 29, 2012 and February 28, 2011 (unaudited)	6
Notes to Condensed Financial Statements	7

3

ABSOLUTE LIFE SOLUTIONS, INC.

CONDENSED BALANCE SHEETS

	February 29, 2012 (unaudited)			August 31, 2011
ASSETS
Current Assets
Cash and cash equivalents	$	2,053,670		$	1,917,896
Accounts receivable		-			1,263,000
Insurance purchase escrow		-			128,750
Receivable under reverse repurchase agreement		-			3,368,593
Investment in life settlement contracts at investment method		3,384,342			-
Prepaid expenses		24,415			45,044
Total current assets		5,462,427			6,723,283
Equipment, net		78,106			90,082
Security deposit		56,688			56,688
Investment in life settlement contracts at fair value		86,270,563			92,708,076
TOTAL ASSETS	$	91,867,784		$	99,578,129
LIABILITIES
Current Liabilities
Accounts payable and accrued expenses	$	192,498		$	44,607
Due to provider		-			568,000
Income taxes payable		19,426			-
Total current liabilities		211,924			612,607
Deferred rent		46,002			42,148
Deferred income taxes		17,232,320			21,071,160
TOTAL LIABILITIES		17,490,246			21,725,915
STOCKHOLDERS’ EQUITY
Preferred stock ($0.00001 par value; 100,000,000 authorized;of which 60,000 are designated as Series A 12.5% convertible preferred stock;  44,450 Series A issued and outstanding ( August 31, 2011 - 41,950 issued and outstanding)		-			-
of which 25,000 are designated as Series B 12.5% convertible preferred stock;  8,850 Series B issued and outstanding ( August 31, 2011 - 8,850 issued and outstanding)		-			-
Common stock ($0.00001 par value; 500,000,000 authorized; 88,625,690 issued and outstanding)   (August 31, 2011 - 85,424,597 issued and outstanding)		886			854
Additional paid in capital		103,439,392			96,773,677
Accumulated deficit		(29,062,740	)		(18,922,317	)
Total Stockholders' Equity		74,377,538			77,852,214
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$	91,867,784		$	99,578,129

The accompanying notes are an integral part of these condensed financial statements.

4

ABSOLUTE LIFE SOLUTIONS, INC.

CONDENSED STATEMENTS OF OPERATIONS

UNAUDITED

	Three months			Three months			Six months ended			Six months ended
	ended February			ended February			February 29,			February 28,
	29, 2012			28, 2011			2012			2011
Sales, general and administrative expenses	$	(509,630	)	$	(708,814	)	$	(884,773	)	$	(1,778,661	)
Other income
Realized gain on life settlement contracts held under investment method		-			-			319,843			-
Change in fair value of life settlement contracts net of premiums paid		(1,349,234	)		10,742,217			(9,229,160	)		31,430,418
Income (loss) before income taxes		(1,858,864	)		10,033,403			(9,794,090	)		29,651,757
Income tax benefit (provision)		272,581			(5,251,490	)		3,819,414			(13,825,451	)
Net income (loss)		(1,586,283	)		4,781,913			(5,974,676	)		15,826,306
Deemed dividend on issuance of Series A and Series B Preferred Stock		(932,643	)		(5,950,000	)		(932,643	)		(19,200,000	)
Dividend on Convertible Preferred Stock		(3,233,104	)		(2,286,018	)		(3,233,104	)		(2,286,018	)
Net income (loss) applicable to common shareholders	$	(5,752,030	)	$	(3,454,105	)	$	(10,140,423	)	$	(5,659,712	)
Basic earnings (loss) per common share	$	(0.06	)	$	(0.04	)	$	(0.11	)	$	(0.06	)
Diluted earnings (loss) per common share	$	(0.06	)	$	(0.04	)	$	(0.11	)	$	(0.06	)
Basic weighted average shares outstanding		93,500,031			88,243,904			92,462,314			87,827,881
Diluted weighted average shares outstanding		93,500,031			88,243,904			92,462,314			87,827,881

The accompanying notes are an integral part of these condensed financial statements.

5

ABSOLUTE LIFE SOLUTIONS, INC.

CONDENSED STATEMENTS OF CASH FLOWS

UNAUDITED

	Six months Ended February 29, 2012			Six months Ended February 28, 2011
OPERATING ACTIVITIES
Net income (loss)	$	(5,974,676	)	$	15,826,306
Adjustments to reconcile net income (loss) to net cash used in operations
Issuances of common stock for services		-			850,530
Unrealized changes in fair value of life settlement contracts		5,211,225			(31,162,556	)
Realized gain on maturity of life settlement contract		-			(2,237,500	)
Realized loss on sale of life settlement contract at fair value		286,496			-
Realized gain on sale of life settlement contracts at investment method		(319,843	)		-
Depreciation		11,976			11,978
Deferred rent		3,854			-
Deferred income taxes		(3,838,840	)		13,762,238
Changes in operating assets and liabilities
Accounts receivable		1,263,000			-
Insurance purchase escrow		128,750			(450,000	)
Prepaid expenses		20,629			(13,544	)
Accounts payable and accrued expenses		147,891			(317,454	)
Income taxes payable		19,426			63,213
Due to provider		(568,000	)		-
Net cash used in operating activities		(3,608,112	)		(3,666,789	)
INVESTING ACTIVITIES
Purchases of life settlement contracts		-			(19,118,000	)
Proceeds from maturity of life settlement contract		-			2,500,000
Proceeds from sale of life settlement contract at fair value		939,792			-
Proceeds from sale of life settlement contracts at investment method		897,234			-
Investment in life settlement contracts at investment method		(458,473	)		-
Investment in reverse repurchase agreement		(134,667	)		-
Net cash provided by (used in) investing activities		1,243,886			(16,618,000	)
FINANCING ACTIVITIES
Proceeds from issuance of preferred stock		2,500,000			19,200,000
Proceeds from shareholder loan		775,000			-
Payment of shareholder loan		(775,000	)		-
Net cash provided by financing activities		2,500,000			19,200,000
Change in cash and cash equivalents		135,774			(1,084,789	)
Cash and cash equivalents, beginning		1,917,896			3,498,525
Cash and cash equivalents, ending	$	2,053,670		$	2,413,736
Supplemental disclosure of non-cash investing activity:
TrTransfer of receivable under reverse repurchase to investment in life settlement contracts at investment method	$	3,503,260		$	-

The accompanying notes are an integral part of these condensed financial statements.

6

ABSOLUTE LIFE SOLUTIONS INC.

NOTES TO THE CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

February 29, 2012

1. NATURE AND CONTINUANCE OF OPERATIONS

Absolute Life Solutions, Inc. (the “Company”) was originally incorporated as Shimmer Gold, Inc. in the State of Nevada on September 7, 2006 and was in the business of the acquisition and exploration of mineral resources.

On May 21, 2010, the Company changed its name from Shimmer Gold, Inc. to Absolute Life Solutions, Inc. During the fiscal year ended August 31, 2010, the Company commenced operations as a specialty financial services company engaged in the business of purchasing life settlement contracts for long-term investment purposes.

The continued existence of the Company is dependent upon its ability to generate profit from its life settlement investments and to meet its obligations as they become due. If additional cash is needed, the Company intends to finance the future capital required to acquire life settlement contracts and continued operations from a combination of traditional debt and equity markets. However, there is no assurance that (a) traditional debt and equity markets may be accessible as required, or if so, on acceptable terms and, or (b) the demand for and selling prices of the Company’s products, may not be sufficient to meet cash flow requirements. The outcome of these matters cannot be predicted with certainty and therefore the Company may not be able to continue or expand operations as planned. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements as of February 29, 2012 and February 28, 2011 and for the three months and six months then ended have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the annual audited financial statements. The unaudited Balance Sheet as of February 29, 2012, Statements of Operations for the three months and six months ended February 29, 2012 and February 28, 2011, and Statements of Cash Flows for the six months ended February 29, 2012 and February 28, 2011, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the period presented. The results for the three months and six months ended February 29, 2012 are not necessarily indicative of results to be expected for the year ending August 31, 2012 or for any future interim period. In addition, the balance sheet data at August 31, 2011 was derived from the audited financial statements but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the Company’s financial statements and notes thereto included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on December 14, 2011.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The most significant estimates with regard to these financial statements relate to deferred income tax amounts and rates and timing of the reversal of income tax differences, the fair value of financial instruments and the determination of the variables used in the calculation of the fair value of life settlement contracts.

7

Cash and Cash Equivalents

The Company considers all short term investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions.

Receivable Under Reverse Repurchase Agreement

Transactions involving purchases of life settlement contracts under agreements to resell (reverse repurchase agreements or reverse repos) are accounted for as collateralized financings except where the Company does not have an agreement to sell the same or substantially the same life settlement contracts before maturity at a fixed or determinable price. The Company's policy is to obtain possession of collateral with a fair value equal to or in excess of the principal amount loaned under resale agreements.

At February 29, 2012 and August 31, 2011 the Company held zero and thirteen life settlement contracts as collateral in the amount of $0 and $3,368,593 respectively, which are reflected as a receivable under reverse repurchase agreement on the Balance Sheets. The counterparty did not exercise its rights under the repurchase agreements and upon expiration of the repurchase agreements, the Company recognized these assets as an investment in life settlement contract at investment method in the aggregate amount of $3,503,250.

The Company follows the provisions of ASC 860, Transfers and Servicing which requires an initial transfer of a financial asset and a repurchase financing that was entered into contemporaneously or in contemplation of the initial transfer to be evaluated as a linked transaction unless certain criteria are met, including that the transferred asset must be readily obtainable in the marketplace.

Life Settlement Contracts

ASC 325-30, Investments in Insurance Contracts allows an investor to elect to account for its investments in life settlement contracts using either the investment method or the fair value method. The election shall be made on an instrument-by instrument basis and is irrevocable. Under the investment method, an investor shall recognize the initial investment at the purchase price plus all initial direct costs. Continuing costs (policy premiums and direct external costs, if any) to keep the policy in force shall be capitalized. Under the fair value method, an investor shall recognize the initial investment at  the purchase  price.  In subsequent periods, the investor shall re-measure the investment at fair value in its entirety at each reporting period and shall recognize the change in fair value in the current period net of premiums paid. The Company primarily uses the fair value method to account for life settlement contracts. For those life settlement contracts held as a receivable under reverse repurchase agreement in the prior period, the Company elected to account for them under the investment method upon expiration of the repurchase agreement. The Company purchased these policies under a reverse repurchase agreement as a short-term investment for the purpose of reselling them to other investors.

Life settlement contracts are inherently long term investments. The individuals upon which the life insurance is underwritten are normally healthy with indications of continuing life spans in excess of 5 years. Accounting for the value of these policies using the fair value method provides a more accurate indication of the present value of these policies as it takes into account the net effect of holding the policy over an extended period during which the investment into the asset is increased, by virtue of continuing premium payments. When life settlement contracts are purchased for the purpose of short term gain, typically in a distressed sale, where the life settlement contracts are sold below market, the fair value method would give an inaccurate valuation as it would price in the distressed opportunity as if this was a normal occurrence in the market. Additionally, the concept of holding the policy for a period of less than one year would create a situation where the asset would be best recorded under the investment method.  

The fair value of the investment in life settlement contracts is evaluated at the end of each reporting period. Realized and unrealized changes in the fair value of the investment are recognized each reporting period in the statements of operations. The fair value is determined on a discounted cash flow basis that incorporates current life expectancy assumptions. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require.

For life settlement contracts accounted under the investment method, the Company will recognize the difference between the death benefits and the carrying value of the policy when the Company determines that settlement and ultimate collection is realizable and reasonably assured. Income from a transaction must meet both criteria in order to be recognized. Income is generally considered realized when cash is received for the sale of a product or performance of a service. Income generally becomes realizable when a promise to pay is received in exchange for the sale of a product or performance of a service. The promise to pay could be verbal (account receivable) or written (note receivable). Income is generally earned when a legally enforceable exchange takes place (e.g., consideration has been tendered and the buyer takes possession of the product or benefits from the performance of a service). The Company recognizes gains from these life settlement contracts that the company owns upon one of the two following events:

1) Receipt of death notice or verified obituary of insured.

2) Signed sale agreement and/or filing of change of ownership forms and funds transferred to escrow.

8

Financial Instruments

The fair value of certain of the Company's financial instruments, consisting of cash, accounts receivable, receivable under reverse repurchase agreement, investments in life settlement contracts at investment method, accounts payable, and accrued expenses are estimated to be equal to their carrying value due to the short-term nature of these instruments. Investments in life settlement contracts at fair value are classified as held-for-trading and measured at fair value, with the realized and unrealized changes in fair value recognized each reporting period in the statements of operations.

The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, Fair Value Measurements and Disclosures which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

It is management's opinion that the Company is not exposed to significant interest, currency and credit risks arising from these financial instruments. (See Note 7).

Deferred Rent Liability

The Company’s operating lease provides for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on the straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense.

Income Taxes

Deferred income taxes are provided for tax effects of temporary differences between the tax basis of asset and liabilities and their reported amounts in the financial statements. The Company uses the liability method to account for income taxes, which requires deferred taxes to be recorded at the statutory rate expected to be in effect when the taxes are paid. Valuation allowances are provided for a deferred tax asset when it is more likely than not that such asset will not be realized.

Management evaluates tax positions taken or expected to be taken in a tax return. The evaluation of a tax position includes a determination of whether a tax position should be recognized in the financial statements, and such a position should only be recognized if the Company determines that it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based upon  the technical merits of the position. For those tax positions that should be recognized, the measurement of a tax position is determined as being the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

Earnings (Loss) per Share

Basic earnings (loss) per share is calculated using the weighted average number of shares of common stock outstanding during the period. Included in basic loss per share calculations are the effects of 6,000,000 warrants exercisable at $.01. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock.  The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. For the three months and six months ended February 29, 2012, 26,650,000 and 27,092,500 warrants with an exercise price of $2.00 and $4.00 respectively, and 53,300 Series A and Series B preferred shares, convertible into 53,300,000 common shares are not included in diluted earnings per share since their effect would be anti-dilutive. For the three months and six months ended February 28, 2011, 16,350,000 warrants with an exercise price of $2.00 and 32,700 Series A preferred shares, convertible into 32,700,000 common shares are not included in diluted earnings per share since their effect would be anti-dilutive.

9

Stock-Based Compensation

The Company accounts for stock based compensation arrangements using a fair value method and records such expense on a straight-line basis over the vesting period.

As of February 29, 2012, the Company has not granted any stock options.

Recent Accounting Pronouncements

The FASB has issued Accounting Standards Update (ASU) No. 2010-15, Financial Services—Insurance (Topic 944): How Investments Held through Separate Accounts Affect an Insurer’s Consolidation Analysis of Those Investments.  This ASU codifies the consensus reached in EITF Issue No. 09-B, "Consideration of an Insurer's Accounting for Majority-Owned Investments When the Ownership Is through a Separate Account." The amendments clarify that an insurance entity generally should not consider any separate account interests held for the benefit of policy holders in an investment to be the insurer's interests and should not combine those interests with its general account interest in the same investment when assessing the investment for consolidation. The general guidance does not apply in instances where the separate account interests are held for the benefit of a related party policy holder as defined in the Variable Interest Entities Subsections of Codification Topic 810, Consolidation,  Subtopic 810-10, as those Subsections require the consideration of related parties. ASU 2010-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2010. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position and results of operations.

Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

3. INVESTMENT IN LIFE SETTLEMENT CONTRACTS

The Company generally purchases life settlement contracts for long-term investment purposes and uses the fair value method to calculate its life settlement portfolio. The Company will also purchase life settlement contracts as a short-term investment for the purpose of reselling them to other investors.

When using fair value to measure assets and liabilities that are not actively trading, the Company follows the principles that clarify methods for measuring fair value when pricing these assets and liabilities. Further, the Company follows standards for the fair value option, which permits all entities to choose to measure eligible items at fair value at specified election dates. These standards state that a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date.

As of February 29, 2012 and August 31, 2011, the Company has the following investments in life settlement contracts at fair value:

	Number of Contracts		Estimated Fair Value		Face Value
August 31, 2011		39	$	92,708,076	$	274,750,633
February 29, 2012		38	$	86,270,563	$	269,742,932

The following table represents the remaining life expectancies for each of the first five succeeding years as of February 29, 2012 for life settlement contracts at fair value:

Number of Contracts	Life Expectancies	Face Value		Carrying Value
-	0-1 years	$	-	$	-
1	1-2 years		10,000,000		5,776,025
2	2-3 years		13,000,000		5,463,816
4	3-4 years		66,200,000		32,293,296
3	4-5 years		16,000,000		5,199,089
28	Thereafter		164,542,932		37,538,337
		$	269,742,932	$	86,270,563

10

The following table represents the remaining life expectancies for each of the first five succeeding years as of February 29, 2012 for life settlement contracts under the investment method:

Number of Contracts	Life Expectancies	Face Value		Carrying Value
-	0-1 years	$	-	$	-
-	1-2 years		-		-
-	2-3 years		-		-
-	3-4 years		-		-
3	4-5 years		8,000,000		1,104,126
8	Thereafter		42,500,000		2,280,216
		$	50,500,000	$	3,384,342

For the three months and six months ending February 29, 2012, the investments experienced an unrealized gain of $730,757 and an unrealized loss of $5,211,225 respectively and the Company paid policy premiums of $1,793,495 and $3,731,439 respectively. For the three months and six months ending February 28, 2011, the investments experienced an unrealized gain of $11,918,186 and $31,162,556 respectively and the Company paid policy premiums of $1,175,969 and $1,969,638 respectively. For the three months and six months ending February 29, 2012, the Company recognized a realized loss of $286,496. For the three months and six months ending February 28, 2011, the Company recognized a realized gain of $0 and $2,237,500 respectively.

The fair value of life settlement contracts is based on information available to the Company at period end. The Company considers the following factors in its fair value estimates: cost at date of purchase; recent purchases and sales of similar investments, financial standing of the issuer, changes in economic conditions affecting the issuer; standard actuarially developed mortality tables and industry life expectancy reports. The Company uses life expectancy reports that have been issued no later than 24 months from the ending date of the quarter being reported. Life expectancy reports are currently ordered from any two of the following life expectancy providers; AVS, 21^st Century, EMSI, ISC and Fasano. The Company considers that the underlying methodology of the life expectancy providers is an adequate gauge for calculating health status of the individual insured. Life expectancy data is used to simulate random possibilities of maturity, which form the basis for a statistical calculation that underlies our market valuations.

The fair value of the life settlement contracts are estimated using present value calculations. The following assumptions were used at February 29, 2012 and August 31, 2011:

	February 29, 2012	August 31, 2011
Dataset	VBT ALB Mortality Table	VBT ALB Mortality Table
Expected premium growth	5%	5%
Mortality rates	Standard life expectancy	Standard life expectancy
Discount rate	16%	14%

In the process of developing a benchmark from which to measure valuation, the Company uses the average redemption yield on the FINRA/Bloomberg High Yield US Corporate Bond Index as a starting point. This index measures the average yield on the highest risk debt obligations traded in the market and serves as a strong indicator of the yield that professional investors would require for similar types of assets. Traditionally, this index yields between 10 – 12%, therefore we added 250 - 350 basis points to the current index yield to account for the current uncharacteristically depressed high yield corporate bond market plus an additional 250 - 350 basis points for the highly illiquid and relatively new life settlements asset class. Our assumption is that short term US Treasuries typically trade in the 250 - 350 BP range. Given the current depressed market rates we have added 250 - 350 BP and will adjust this inversely to the short term Treasuries. As Treasuries rise the spread rate will diminish keeping the discount rate in line with the market. As the life settlement market continues to mature and the investment pools will become better managed the risk will diminish and the asset class will become more liquid. Current market players are better capitalized and understand the asset characteristics at a higher level. As such the discount rate should reflect a maturing market.

The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life settlement contracts and the Company’s estimate of the risk premium an investor in the policy would require. The Company believes that investors in alternative investments typically target yields averaging between 13 - 16% for investments of more than a 5 year duration. A 16% rate of return over a five year duration is a reasonable target for investments that are highly illiquid, relatively new and more volatile (i.e. life settlement contracts) than standard investments. In recent months, there have been a number of government investigations of several life settlement companies. These investigations, and subsequent SEC charges, in one instance, have caused a temporary dislocation in the life settlement market. Liquidity has tightened even further. In light of these factors, the Company believes the perceived risk or uncertainty over these assets has changed and therefore the risk premium an investor would require has changed, therefore management made a change in accounting estimate and adjusted its discount rate from 14% to 16% in the first quarter ending November 30, 2011, since management believes that a more conservative discount rate is appropriate due to the continued credit crunch in the market and in discussions with other investors in the life settlements market. The Company will continue to periodically assess the discount rate applied to its portfolio of life insurance policies which may result in future changes in fair value. The Company believes that this dislocation is temporary but is unable to predict how long it will take the market to return to a more traditional level. In the event that the dislocation and the market returns to a more traditional level, management will reevaluate the discount rate it uses in valuing its life settlement contracts.

11

The result of applying these assumptions and using Monte Carlo simulations for the quarter ended February 29, 2012 and year ended August 31, 2011 is as follows:

	February 29, 2012			August 31, 2011
Total Pool Benefit	$	269,742,932		$	274,750,633
Average predicted period until final pool maturity		8.16 yrs			9.03 yrs
Average simulated maturities over age 90		53	%		54	%
Average age at February 29, 2012 and August 31, 2011		82			82
Average age at maturity		91			91

The assumptions are, by their nature, inherently uncertain and the effect of changes in estimates may be significant. The fair value measurements used in estimating the present value calculations are derived from valuation techniques that include inputs for the asset that are not based on observable market data. The risks associated with the investments in life settlement contracts arise from the unknown remaining life expectancy, a change in credit worthiness of the policy issuer, funds needed to maintain the asset, and changes in the discount rate (See Note 7).

4. PREFERRED STOCK

The total number of preferred shares authorized and that may be issued by the Company is 100,000,000 preferred shares with a par value of $0.00001. These preferred shares have no rights to voting, profit sharing or liquidation.

Of the total preferred shares authorized, pursuant to a Certificate of Designation dated July 22, 2010, 60,000 preferred shares have been designated as Series A 12.5% convertible preferred stock (the “Series A Preferred Stock”), with a par value of $0.00001. Effective April 7, 2011, an additional 25,000 preferred shares have been designated as Series B 12.5% convertible preferred stock (the “Series B Preferred Stock”), with a par value of $0.00001. In connection with the establishment of the Series B Preferred Stock, which is subordinate to the Series A Preferred Stock in respect of liquidation and redemption, the holders of 6,000 shares of Series A Preferred Stock agreed to exchange their Series A Preferred Stock for Series B Preferred Stock.  As a result, each exchanging Series A holder becomes a Series B holder and is entitled to receive an additional 50 Series B warrants exercisable at $4.00 for each share of preferred stock so exchanged. During the year ended August 31, 2011, the Company issued 34,450 shares of Series A  Preferred Stock, of which holders of 6,000 shares have agreed to exchange for Series B Preferred Stock and issued 2,850 of Series B Preferred Stock. In connection with the issuance of each Series A Preferred Stock, the Company issued 1,000 warrants (500 exercisable at $2.00 per share and 500 exercisable at $4 per share of common stock). In connection with the issuance of each share of Series B  Preferred Stock, the Company issued 1,050 warrants (500 exercisable at $2.00 per share and 550 exercisable at $4 per share of common stock).

The Series A convertible preferred shares were issued at $1,000 per share and each Series A convertible share is convertible into 1,000 shares of common stock at an initial conversion price of $1.00 per share. The Series A convertible preferred shares are convertible at the election of the holder. The conversion right is effective beginning on the earlier of 65 days after the initial issuance of the shares to the holder or the effective date of a registration statement filed by the Company covering the holder’s resale of the conversion shares. The earlier of the two dates will be the Conversion Date.

The holders of the shares of Series A Preferred Stock have the right to redeem the Series A Preferred Stock only upon existence of a Redemption Event. A Redemption Event is within control of the Company. A Redemption Event is described as:

(a) Failure of the Company to deliver certificates of conversion to the holders for any reason within 15 days after the Conversion Date and the holder has given 5 days’ notice thereof;

(b) A change in beneficial ownership of more than 50% of the common stock of the Company within a period of 40 trading days or involuntary change in a majority of the members of the Board of Directors of the Company within a period of 40 days; or

(c) Bankruptcy, reorganization, insolvency or liquidation proceedings which are not dismissed within 60 days.

12

If the holder redeems the Series A preferred shares, the Company will be obligated to pay the holder a redemption amount equal to the sum of (i) the stated value of the redeemed shares multiplied by 102%, if the redemption occurs within 5 years from the initial issuance; (ii) or by 100% if the redemption occurs after the 5 years. In addition, upon redemption, the Company must pay unpaid dividends through the date of such payment.

Dividends are payable at the rate of 12.5% per annum, in cash or in common stock, at the option of the Company. Dividends are payable semi-annually on the last day of June and December.

The Series A Preferred Stock does not have a maturity or mandatory redemption date, except upon certain limited acts of default. The Series A Preferred Stock does have a cash settlement provision.

The Series B convertible preferred shares were issued at $1,000 per share and each Series B convertible share is convertible into 1,000 shares of common stock at an initial conversion price of $1.00 per share. The Series B convertible preferred shares are convertible at the election of the holder. The conversion right is effective beginning on the earlier of 65 days after the initial issuance of the shares to the holder or the effective date of a registration statement filed by the Company covering the holder’s resale of the conversion shares. The earlier of the two dates will be the Conversion Date.

The holders of the shares of Series B Preferred Stock have the right to redeem the Series B Preferred Stock only upon existence of a Redemption Event. A Redemption Event is within control of the Company. A Redemption Event is described as:

(a) Failure of the Company to deliver certificates of conversion to the holders for any reason within 15 days after the Conversion Date and the holder has given 5 days’ notice thereof;

(b) A change in beneficial ownership of more than 50% of the common stock of the Company within a period of 40 trading days or involuntary change in a majority of the members of the Board of Directors of the Company within a period of 40 days; or

(c) Bankruptcy, reorganization, insolvency or liquidation proceedings which are not dismissed within 60 days.

If the holder redeems the Series B preferred shares, the Company will be obligated to pay the holder a redemption amount equal to the sum of (i) the stated value of the redeemed shares multiplied by 102%, if the redemption occurs within 5 years  from the  initial issuance;  (ii) or by  100% if  the redemption occurs after the 5 years. In addition, upon redemption, the Company must pay unpaid dividends through the date of such payment.

Dividends are payable at the rate of 12.5% per annum, in cash or in common  stock, at the option of the Company. Dividends are payable semi-annually on the last day of June and December.

The Series B Preferred Stock does not have a maturity or mandatory redemption date, except upon certain limited acts of default. The Series B Preferred Stock does have a cash settlement provision.

During the six months ended February 29, 2012, the issuance of 2,500 Series A Preferred Shares for aggregate proceeds of $2,500,000 with a contractual conversion price of $1.00 resulted in an effective conversion price lower than the fair market value of the Company’s Common Stock at each issuance after allocating the proceeds received to the preferred shares and the detachable warrants included with the preferred shares. Accordingly, the Company recorded deemed dividends in the aggregate amount of $932,643 attributable to the beneficial conversion feature.

5. COMMON STOCK

A.   The Company did not issue additional common stock during the six months ended February 29, 2012.

On December 22, 2011, the Board of Directors authorized that the Company issue 3,201,093 shares of common stock as payment of the 12.5% dividend for December 31, 2011 on the Series A Preferred Stock and Series B Preferred Stock.

B.    Warrant transactions are summarized as follows:

	Number of  warrants		Weighted average exercise price		Weighted average life remaining (in years)
Balance as at August 31, 2011
Issued		57,242,500		2.69		4.33 years
Additions as of February 29, 2012
Issued		2,500,000		-		5.00 years
Balance as at February 29, 2012		59,742,500		2.71		3.80 years

13

As of February 29, 2012, there were 59,742,500 warrants outstanding and exercisable with expiration dates commencing June 2015 through February 2017. If a Registration Statement is not effective at the time of exercise, the holder may elect a “cashless exercise” resulting in no additional proceeds from the warrant exercise received by the Company.

Except as set forth, the warrants do not permit net cash settlement.

6. COMMITMENTS

 Life insurance premiums are future payments required to keep the insurance policies, comprising the Company’s investment in life settlement contracts, intact. At February 29, 2012, the premiums to be paid for each of the five succeeding fiscal years ending August 31for investment in life settlement contracts at fair value are as follows:

Year	Amount
2012	$	8,810,109
2013		17,581,956
2014		17,543,693
2015		17,543,693
2016		17,543,693
Thereafter		196,759,667
	$	275,782,811

At February 29, 2012, the premiums to be paid for each of the five succeeding fiscal years ending August 31for investment in life settlement contracts at investment method are as follows:

Year	Amount
2012	$	1,388,486
2013		2,776,971
2014		2,776,971
2015		2,776,971
2016		2,776,971
Thereafter		35,246,528
	$	47,742,898

7. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following table provides an analysis of Level 3 financial instruments that are re-measured subsequent to initial recognition at fair value. The Company determined that its investment in life settlements at fair value is a Level 3 financial instrument and that it has no Level 1 or Level 2 financial instruments:

Reconciliation of Level 3 fair value measurements of financial assets on a recurring basis using unobservable inputs as of February 29, 2012 and August 31, 2011:

Unquoted Life Settlement Contracts:	February 29, 2012			August 31, 2011
Beginning balance	$	92,708,076		$	12,313,897
Transfers in:
Purchases of life settlement contracts		-			29,791,549
Change in fair value of life settlement contracts		(5,497,721	)		53,102,630
Transfers out:
Proceeds from sale of life settlement contract		(939,792	)		-
Proceeds from maturity of life settlement contract		-			(2,500,000	)
Ending balance	$	86,270,563		$	92,708,076

14

The extent to which the fair value could reasonably vary in the near term has been quantified by evaluating the effect of changes in significant underlying assumptions used to estimate the amount. If the discount factors were increased or decreased by 2% while all other variables are held constant, the carrying value of the investment in life settlement policies would be:

	Discount Rate as of February 29, 2012				Discount rate as of August 31, 2011
	+ 2%		(2%)		+ 2%		(2%)
Investment in Life Settlement Contracts	$	79,922,024	$	93,453,519	$	85,215,603	$	101,271,273

The Company utilizes the MAPS system for valuations. MAPS is a generally accepted third party pricing system utilized by funds and investors engaged in the purchase and sale of life settlements.

Life expectancy reports are generated by third party medical underwriting firms, such as AVS, 21 ^st Century, EMSI and Fasano. These firms review medical data for an individual and grade using a series of debits and credits. The resulting values are used to generate a life expectancy value. The MAPS system utilizes this life expectancy data to calibrate underlying mortality curves generated for each individual case.

MAPS utilizes the appendixes to the VBT2008 report as a base for mortality projections. This chart established 25 unique values corresponding to 25 statistical values indicative of the next 25 years of a persons life. The value is the statistical probability that the individual will meet an untimely end in that given year. When a life expectancy provider produces a report, it indicates a value at which point a certain individual will achieve a 50% chance, statistically, of dying. This is calculated by randomly making 1000 simulations and calculating an exact point of death for each simulation. The point at which the cumulative deaths equal 500 is the median point or the life expectancy.

In order to calibrate this curve, a multiplier is formulated to cause the median mark to equal the life expectancy value provided by the life expectancy provider. For every case, 1000 simulations are run, each simulation resulting in a unique death month. For example, if a life expectancy equals 50 months, the underlying data would show 500 deaths prior to the 50th month and 500 deaths after the 50th month.

The MAPS system takes the results of the modified life expectancy curve and applies it to the premium and death benefit projections stream. For the 500 deaths prior to the 50th month, utilizing our previous example, it would apply the percentage of the simulated runs that died in each 12 month period to the death benefit and premium schedules to form estimated cash flows. The net present value, using a discount rate defined by the user, of the streams of values created by this method form the indicated value of the policy.

8. INCOME TAXES

Income tax (benefit) expense consists of the following components at February 29, 2012 and 2011:

	2012			2011
Current tax expense	$	19,426		$	63,213
Deferred tax (benefit) expense		(3,838,840	)		13,762,238
Total income tax (benefit) expense	$	(3,819,414	)	$	13,825,451

The Company calculates its interim tax provision in accordance with the provisions of ASC 740-270, Income Taxes; Interim Reporting . For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items we report separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.

In computing the annual estimated effective tax rate the Company makes certain estimates and judgments, such as estimated annual taxable income or loss, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. These estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. The difference between the statutory rate of 35% and the effective rate of 40% is primarily attributable to the affect of state and local taxes.

As of February 29, 2012, the Company has filed income tax returns through the fiscal 2009 tax year. The Company is required to file income tax returns in the United States (federal) and in New York State and City. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The evaluation was performed for the August 31, 2007 – August 31, 2011 tax years, which remain subject to examination. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position.

15

The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There are no significant amounts accrued for penalties or interest as of or during the three months and six months ended February 29, 2012 and February 28, 2011. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

9. RELATED PARTY TRANSACTIONS

During the quarter ended February 29, 2012, the Company received short-term loans from a shareholder of $775,000. The loans were at a rate of 8% per annum with a maturity date ending on or before February 29, 2012. The Company paid the loans in full as of February 29, 2012. Interest expense of $2,800 is included in sales, general and administrative expenses on the Condensed Statements of Operations.

10. SUBSEQUENT EVENTS

The Company evaluates events that have occurred after the balance sheet date through the date the financial statements were publicly available. Based upon the evaluation, the Company did not identify any other recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements .

16

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Special Note:  Certain statements in this quarterly report on Form 10-Q concerning our business prospects or future financial performance, anticipated revenues, expenses, profitability or other financial items, estimates as to size, growth in or projected revenues from the life settlement market, developments in industry regulations and the application of such regulations, expected outcomes of pending or potential litigation and regulatory actions, and our strategies, plans and objectives, together with other statements that are not historical facts, are “forward-looking statements” as that term is defined under the federal securities laws.  All of these forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements.  You should carefully review the risks described herein and in other documents we file from time to time with the Securities and Exchange Commission, (“ SEC ”), including our Annual Report on Form 10-K for the year ended August 31, 2011 (“ Fiscal 2011 ”), particularly in the sections entitled “Item 1A – Risk Factors” and “Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations.” 

Unless required by law, we undertake no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this Report or to reflect the occurrence of unanticipated events. Shareholders and potential shareholders should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this Report. Management cautions that these statements are qualified by their terms and/or important factors, many of which are outside of our control, and involve a number of risks, uncertainties and other factors that could cause actual results and events to differ materially from the statements made, including, but not limited to, the following:

· actual or anticipated fluctuations in our quarterly and annual operating results;

· actual or anticipated product constraints;

· decreased demand resulting from changes in laws;

· product and services announcements by us or our competitors;

· loss of any of our key executives;

· regulatory announcements, proceedings or changes;

· competitive product developments and legal developments;

· any business combination we may propose or complete;

· any financing transactions we may propose or complete; or

· broader industry and market trends unrelated to its performance.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

Results of Operations

Our results of operations for the three months and six months ended February 29, 2012, consisted of change in fair value of life settlement contracts net of premiums paid (which include unrealized gains on life settlement contracts and realized gains on sale of life settlement contracts), less operating and administrative expenses for personnel, leased office space and professional fees and income tax expense.

17

Three months and six months ended February 29, 2012 compared to three months and six months ended February 28, 2011

ABSOLUTE LIFE SOLUTIONS, INC.

	Three months			Three months			Six months ended			Six months ended
	ended February			ended February			February 29,			February 28,
	29, 2012			28, 2011			2012			2011
Sales, general and administrative expenses	$	(509,630	)	$	(708,814	)	$	(884,773	)	$	(1,778,661	)
Other income
Realized gain on life settlement contracts held under investment method		-			-			319,843			-
Change in fair value of life settlement contracts net of premiums paid		(1,349,234	)		10,742,217			(9,229,160	)		31,430,418
Income (loss) before income taxes		(1,858,864	)		10,033,403			(9,794,090	)		29,651,757
Income tax benefit (provision)		272,581			(5,251,490	)		3,819,414			(13,825,451	)
Net income (loss)		(1,586,283	)		4,781,913			(5,974,676	)		15,826,306
Deemed dividend on issuance of Series A and Series B Preferred Stock		(932,643	)		(5,950,000	)		(932,643	)		(19,200,000	)
Dividend on Convertible Preferred Stock		(3,233,104	)		(2,286,018	)		(3,233,104	)		(2,286,018	)
Net income (loss) applicable to common shareholders	$	(5,752,030	)	$	(3,454,105	)	$	(10,140,423	)	$	(5,659,712	)
Basic earnings (loss) per common share	$	(0.06	)	$	(0.04	)	$	(0.11	)	$	(0.06	)
Diluted earnings (loss) per common share	$	(0.06	)	$	(0.04	)	$	(0.11	)	$	(0.06	)
Basic weighted average shares outstanding		93,500,031			88,243,904			92,462,314			87,827,881
Diluted weighted average shares outstanding		93,500,031			88,243,904			92,462,314			87,827,881

Expenses: Operating and administrative expenses decreased from $708,814 and $1,778,661 for the three months and six months ended February 28, 2011 respectively to $509,630 and $884,773 for the three months and six months ended February 29, 2012 respectively. The decrease of approximately $200,000 and $900,000 respectively is primarily attributable to a decrease in spending on marketing budgets of approximately $65,000 and $770,000 respectively. Marketing expenses related to the initial start-up of the Company were incurred in the first six months of the prior year. These were one time charges. This was offset by an increase in NYS capital tax of approximately $100,000 in the three months and six months ended February 29, 2012. Additionally, in the six months ended February 28, 2011, we issued common stock as compensation to an investor relations consultant and to a board member, of which the fair value of that stock compensation was approximately $200,000. We did not issue any stock compensation in the six months ended February 29, 2012.

Other Income (Loss): Total other income decreased from $10,742,217 and $31,430,418 for the three months and six months ended February 28, 2011 respectively to a loss of $1,349,234 and $8,909,317 for the three months and six months ended February 29, 2012 respectively. Change in fair value net of premiums paid including realized losses of $286,496 were $1,349,234 and $9,229,160 for the three months and six months ended February 29, 2012 respectively, due to fair market valuation of pool policies. We had a net realized loss of $286,496 from the sale of one policy held at fair value for the three months and six months ended February 29, 2012 and net realized gains of $319,843 from the sale of two policies held under investment method for the six months ended February 29, 2012. The decrease in fair value of our life settlement portfolio is primarily attributable to the increase in discount rate that the Company utilizes in valuing its investments. Additionally, the Company made no new acquisitions of policies in the three months and six months ended February 29, 2012 as compared to acquisitions of 5 and 21 new policies in the three months and six months ended February 28, 2011 respectively. These were acquisitions of policies in distressed sales from individuals/entities that did not have the ability to “hold” the policies. When these policies were initially marked at fair value, there were significant unrealized gains because of our intent and ability to hold these policies until maturity. In subsequent periods, the gradual changes in fair value will result in a decrease in the change in unrealized gains on policies already acquired.

18

Income Tax: Income tax expense decreased from $5,251,490 and $13,825,451 for the three months and six months ended February 28, 2011 respectively to a benefit of $272,581 and $3,819,414 for the three months and six months ended February 29, 2012 respectively. The decrease is primarily attributable to the decrease in unrealized gains on life settlement contracts for the three months and six months ended February 29, 2012 as compared to the three months and six months ended February 28, 2011.

Net Income (Loss): We reported a net loss of $1,586,283 and $5,974,676 for the three months and six months ended February 29, 2012 respectively compared to net income of $4,781,913 and $15,826,306 for the three months and six months ended February 28, 2011 respectively. The decrease of approximately $6.4 million and $21.8 million is primarily attributable to a decrease of approximately $11.7 million and $38.1 million in unrealized gains and approximately $0 and $2.2 million in realized gains offset by a decrease of approximately $5.5 million and $17.6 million in income tax expense and approximately $200,000 and $890,000 in general and administrative expenses. Refer to preceding discussions for explanation of variances.

Deemed Dividend. Deemed dividend decreased from $5,950,000 and $19,200,000 for the three months and six months ended February 28, 2011 respectively to $932,643 for the three months and six months ended February 29, 2012 respectively. The decrease is a result of the Company only issuing $2.5 million of preferred shares for the three months and six months ended February 29, 2012 as compared to the issuance of $5,950,000 and $19,200,000 of preferred shares for the three months and six months ended February 28, 2011 respectively. The Company records a deemed dividend for financial statement purposes to holders of our Series A preferred shares in connection with the appreciation of our common stock price. The deemed dividend reflects the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.

Liquidity and Capital Resources

Net cash used in operating activities for the six months ended February 29, 2012 was $3,608,112. Net cash provided by investing activities was $1,243,886 arising from proceeds received from sale of life settlement contracts partially offset by payment of premiums for life settlement contracts held at investment method and payment of premiums for life settlement contracts held under reverse repurchase agreements. Net cash provided by financing activities was $2,500,000 from the sale of Series A Preferred Stock. This resulted in an increase in cash of $135,774. During the quarter ended February 29, 2012, we received loans from a shareholder of $775,000. We paid the loans in full as of February 29, 2012.

The Company establishes and analyzes its premium reserves on a monthly basis. Once an adequate reserve level is met, the Company weighs additions to its portfolio based on the future value of the investment and the future impact the premium commitment will have on its liquidity. Since the Company is still building a carefully weighted portfolio it must meet future liquidity needs through the issuance of debt instruments and the sale of equity. It is anticipated that as the pool of policies expands and policies mature the resultant cash flows will enable the Company to satisfy the Company’s liquidity needs though such maturities, but because of the variability of life expectancy we cannot predict the date when this will occur.

Working Capital and Capital Availability: As of February 29, 2012, we had working capital of $5,250,503, including $3,384,342 of policies held under the investment method. Subsequent to quarter end, we sold one policy, which was held at fair value, for $920,000. We expect to raise additional funds to continue to build our portfolio through debt or subsequent equity offerings. Such issuance may dilute the interest of our existing shareholders. During the next twelve months we anticipate that we will not generate significant cash from operations. The Company has in the past and expects to in the future find opportunities to purchase policies at advantageous prices. In order to finance future operations, the Company may sell these policies to other investors as these situations present a short term gain that exceeds the projected long term benefit. We expect to continue to build a portfolio of life settlements that will mature over the following ten year period. While we may derive income from early maturities, the policies will generally have a life expectancy exceeding 3 years. As our portfolio matures, we expect that our capital needs will subside.

Going Concern Qualification

Our financial statements for the period ended February 29, 2012 indicate that the activities of the Company did not generate positive cash flow from operations, and that we incurred losses in developing this business. The Company will require additional funds to finance its operations. These conditions raise substantial doubt about our ability to continue as a going concern. Since July 2010, we have raised in excess of $50,000,000 in additional capital, a portion of which is available for our working capital needs. The Company has undertaken further steps with the goal of sustaining our operations for the next twelve months and beyond to address its lack of liquidity by raising additional funds, either in the form of debt or equity or by selling our policies to other investors. However, there can be no assurance that the Company can successfully accomplish these steps and or business plans, and it is uncertain that the Company will achieve a profitable level of operations and be able to obtain additional financing. There can be no assurance that any additional financings will be available to the Company on satisfactory terms and conditions, if at all.

19

Application of Critical Accounting Policies and Estimates

Our discussion and analysis of financial condition and results of operations are based on our condensed financial statements that were prepared in accordance with accounting principles generally accepted in the United States of America.  To guide our preparation, we follow accounting policies, some of which represent critical accounting policies as defined by the SEC.  The SEC defines critical accounting policies as those that are both most important to the portrayal of a company’s financial condition and results and require management’s most difficult, subjective, or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.  Certain accounting estimates involve significant judgments, assumptions and estimates by management that may have a material impact on the carrying value of certain assets and liabilities, disclosures of contingent liabilities, and the reported amounts of income and expenses during the reporting period that management considers critical accounting estimates.  The judgments, assumptions and estimates used by management are based on historical experience, management’s experience, knowledge of the accounts and other factors that are believed to be reasonable.  Because of the nature of the judgments and assumptions made by management, actual results may differ materially from these judgments and estimates, which could have a material impact on the carrying values of assets and liabilities and the results of our operations.  Areas affected by our estimates and assumptions are identified below.

ASC 325-30, Investments in Insurance Contracts, states that an investor may elect to account for its investments in life settlement contracts using either the investment method or the fair value method.  The election is to be made on an instrument-by instrument basis and is irrevocable.  Under the investment method, an investor is to recognize the initial investment at the purchase price plus all initial direct costs.  Continuing costs (e.g., policy premiums and direct external costs, if any) to keep the policy in force are to be capitalized.  Under the fair value method, an investor recognizes the initial investment at the purchase price.  In subsequent periods, the investor re-measures the investment at fair value in its entirety at each reporting period and recognizes change in fair value earnings (or other performance indicators for entities that do not report earnings) in the period in which the changes occur.  We primarily value our investments in life settlement contracts using the fair value method. As of February 29, 2012 and August 31, 2011, the total of our investment in life settlements held for our own account held at fair value was valued at $86,270,563 and $92,708,076, respectively. As of February 29, 2012 and August 31, 2011, the total of our investment in life settlements held for our own account held at investment method was valued at $3,384,342 and $0, respectively.

The fair value of the investment in life settlement contracts is evaluated at the end of each reporting period. Realized and unrealized changes in the fair value of the investment are recognized each reporting period in the statements of operations. The fair value is determined on a discounted cash flow basis that incorporates current life expectancy assumptions. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require. In the process of developing a benchmark from which to measure valuation, the Company uses the average redemption yield on the FINRA/Bloomberg High Yield US Corporate Bond Index as a starting point. This index measures the average yield on the highest risk debt obligations traded in the market and serves as a strong indicator of the yield that professional investors would require for similar types of assets. Traditionally, this index yields between 10 – 12%, therefore we added 250 - 350 basis points to the current index yield to account for the current uncharacteristically depressed high yield corporate bond market plus an additional 250 - 350 basis points for the highly illiquid and relatively new life settlements asset class. Our assumption is that short term US Treasuries typically trade in the 250 - 350 BP range. Given the current depressed market rates we have added 250 - 350 BP and will adjust this inversely to the short term Treasuries. As Treasuries rise the spread rate will diminish keeping the discount rate in line with the market. As the life settlement market continues to mature and the investment pools will become better managed the risk will diminish and the asset class will become more liquid. Current market players are better capitalized and understand the asset characteristics at a higher level. As such the discount rate should reflect a maturing market.

The Company believes that investors in alternative investments typically target yields averaging between 13 - 16% for investments of more than a 5 year duration. A 16% rate of return over a five year duration is a reasonable target for investments that are highly illiquid, relatively new and more volatile (i.e. life settlement contracts) than standard investments. In recent months, there have been a number of government investigations of several life settlement companies. These investigations, and subsequent SEC charges, in one instance, have caused a temporary dislocation in the life settlement market. Liquidity has tightened even further. In light of these factors, the Company believes the perceived risk or uncertainty over these assets has changed and therefore the risk premium an investor would require has changed, therefore we made a change in accounting estimate and adjusted our discount rate from 14% to 16% in the first quarter ending November 30, 2011, since we believe that a more conservative discount rate is appropriate due to the continued credit crunch in the market and in discussions with other investors in the life settlements market. The Company will continue to periodically assess the discount rate applied to its portfolio of life insurance policies which may result in future changes in fair value. The Company believes that this dislocation is temporary but is unable to predict how long it will take the market to return to a more traditional level. In the event that the dislocation and the market returns to a more traditional level, we will reevaluate the discount rate we use in valuing our life settlement contracts.

The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, Fair Value Measurements and Disclosures, which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

20

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example cash flow modeling inputs based on assumptions)

The following table provides an analysis of Level 3 financial instruments that are re-measured subsequent to initial recognition at fair value. The Company determined that its investment in life settlements is a Level 3 financial instrument and that it has no Level 1 or Level 2 financial instruments:

Reconciliation of Level 3 fair value measurements of financial assets on a recurring basis using unobservable inputs as of February 29, 2012 and August 31, 2011:

Unquoted Life Settlement Contracts:	February 29, 2012			August 31, 2011
Beginning balance	$	92,708,076		$	12,313,897
Transfers in:
Purchases of life settlement contracts		-			29,791,549
Change in fair value of life settlement contracts		(5,497,721	)		53,102,630
Transfers out:
Proceeds from sale of life settlement contract		(939,792	)		-
Proceeds from maturity of life settlement contract		-			(2,500,000	)
Ending balance	$	86,270,563		$	92,708,076

We make estimates of the collectability of insurance proceeds receivable.  The accounts associated with these areas are critical to recognizing the correct amount of revenue in the proper period.  We have not experienced any material changes in our estimates of collectability versus actual results in the current or prior periods.

We review the carrying value of the property and equipment for impairment whenever events and circumstances indicate that the carrying value of an asset may not be recoverable from the estimated future cash flows expected to result from its use and eventual disposition.  In cases where undiscounted expected future cash flows are less than the carrying value, an impairment loss is recognized equal to an amount by which the carrying value exceeds the fair value of assets.  The factors considered by management in performing this assessment includes current operating results, trends and prospects, the manner in which the property is used, and the effects of obsolescence, demand, competition and other economic factors.  Based on this assessment, there was no impairment during the three months and six months ended February 29, 2012.

We evaluate the useful lives of our property and equipment to assure that an adequate amount of depreciation is being charged to operations.  Useful lives are based generally on specific knowledge of an asset’s life in combination with the Internal Revenue Service rules and guidelines for depreciable lives for specific types of assets.

We are required to estimate our income taxes.  This process involves estimating our current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes.  These differences result in deferred tax assets and liabilities.  We then assess the likelihood that our deferred tax assets will be recovered from future taxable income, and, to the extent we believe that recovery is not likely, we establish a valuation allowance.  To the extent we establish a valuation allowance or increase this allowance in a period, we include a tax provision or reduce our tax benefit in the statements of operations.  We use our judgment to determine our provision or benefit for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.

We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations.  We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.

We have not made any material changes to our critical accounting estimates or assumptions or the judgments affecting the application of those estimates or assumptions.

21

New Accounting Pronouncements

The FASB has issued Accounting Standards Update (ASU) No. 2010-15, Financial Services—Insurance (Topic 944): How Investments Held through Separate Accounts Affect an Insurer’s Consolidation Analysis of Those Investments. This ASU codifies the consensus reached in EITF Issue No. 09-B, "Consideration of an Insurer's Accounting for Majority-Owned Investments When the Ownership Is through a Separate Account." The amendments clarify that an insurance entity generally should not consider any separate account interests held for the benefit of policy holders in an investment to be the insurer's interests and should not combine those interests with its general account interest in the same investment when assessing the investment for consolidation. The general guidance does not apply in instances where the separate account interests are held for the benefit of a related party policy holder as defined in the Variable Interest Entities Subsections of Codification Topic 810,  Consolidation,  Subtopic 810-10, as those Subsections require the consideration of related parties. ASU 2010-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2010. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position and results of operations.

Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

Off-Balance Sheet Arrangements

We did not engage in any off-balance sheet arrangements or transactions.

Outlook

We believe our company and our industry are fundamentally sound and well positioned to deal with the current uncertainty in the financial and capital markets.  Our life settlements are not correlated to the financial or commodities markets, which increases their appeal in uncertain times.  We carry no operational debt and do not rely on leverage in our capital structure.  We do rely, however, upon the availability of investment capital.  While it is conceivable that a deep financial crisis could diminish the supply of investment capital throughout the economy, our experience during the six months ended February 29, 2012 indicates that greater investment capital will be placed in life settlements.  We believe this is due to the fact that returns in life settlements are relatively attractive and not correlated to the performance of the financial markets. As a result, we believe we will have an adequate amount of cash provided we are able to source capital or sell policies.

Our operating strategy is to increase cash flows generated from operations by increasing revenues while controlling operating and administrative expenses.  We believe that domestic and international demand for life settlements will continue to grow as the prospects for economic conditions remain uncertain and investors look for alternative investments.    On the supply side, we are increasing our advertising and professional awareness marketing to potential sellers of policies and to strengthen our broker network.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

Not applicable.

Item 4. Controls and Procedures.

Disclosure Controls and Procedures.  With the participation of our Chief Executive Officer and Chief Accounting Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”)), as of the end of the period covered by this report.  Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of such periods, our disclosure controls and procedures were not effective due to the material weaknesses noted below, in ensuring that (i) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

· Due to the small size of its staff, the Company did not have sufficient segregation of duties to support its internal control over financial reporting.

There were no changes in our internal controls over financial reporting during the quarter ended February 29, 2012, that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

22

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

The Company is not engaged in any legal proceedings.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

During the quarter ended February 29, 2012, we entered into Securities Purchase Agreements with certain purchasers pursuant to which we sold an aggregate of (i) 2,500 shares of our Series A Preferred Stock, which shares of Series A Preferred Stock have a stated value of $1,000 per share and are convertible into shares of our Common Stock at an initial conversion price of $1.00 per share, and (ii) warrants to purchase an aggregate of 2,500,000 shares of common stock, half of which are exercisable at an initial exercise price of $2.00 per share and half of which are exercisable at an initial exercise price of $4.00 per share, which Investor Warrants expire five (5) years after issuance.

Item 3. Defaults Upon Senior Securities.

The Company currently does not have senior securities

Item 5. Other Information.

Item 6. Exhibits.

Exhibit Number	Description
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act .

23

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.

ABSOLUTE LIFE SOLUTIONS, INC.
April 23, 2012	/s/ Joshua Yifat
	Joshua Yifat
	Treasurer and Chief Financial Officer (Principal Financial Officer)

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Capacity in which signed	Date
/s/ Avrohom Oratz
Avrohom Oratz	President and Chief Executive Officer (Principal Executive Officer )	April 23, 2012

24

EX-31.1

Exhibit 31.1

CERTIFICATION OF

CHIEF EXECUTIVE  OFFICER

 PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Avrohom Oratz, certify that:

1. I have reviewed this Form 10-Q of Absolute Life Solutions, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods present in this report;

4. The issuer’s other certifying officer(s) and I are  responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the issuer and have:

a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c. Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d. Disclosed in this report any change in the issuer’s internal control over financing reporting that occurred during the issuer’s most recent fiscal quarter (the issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the issuer’s internal control over financial reporting; and

5. The issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent functions):

a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and

b. Any fraud, whether or not material, that involved management or other employees who have a significant role in the issuer’s internal control over financial reporting.

Date: April 23, 2012

/s/ Avrohom Oratz

Avrohom Oratz

President and Chief Executive Officer (principal executive officer  and duly
authorized officer)

EX-31.2

Exhibit 31.2

CERTIFICATION OF

CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

I, Joshua Yifat, certify that:

1. I have reviewed this Form 10-Q of Absolute Life Solutions, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods present in this report;

4. The issuer’s other certifying officer(s) and I are  responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the issuer and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the issuer’s internal control over financing reporting that occurred during the issuer’s most recent fiscal quarter (the issuer’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the issuer’s internal control over financial reporting; and

5. The issuer’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the issuer’s auditors and the audit committee of the issuer’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the issuer’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the issuer’s internal control over financial reporting.

Date: April 23, 2012

/s/ Joshua Yifat

Joshua Yifat

Treasurer and Chief Financial 

Officer (principal  financial

officer and duly authorized officer)

EX-32.1

Exhibit 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Absolute Life Solutions, Inc., for the quarter ending February 29, 2012, I, Avrohom  Oratz, President and Chief Executive Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

1.    Such Quarterly Report on Form 10-Q for the quarter ending February 29, 2012, fully complies with the requirements of  Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.    The information contained in such Quarterly Report on Form 10-Q for the quarter  ending February 29, 2012, fairly represents in all material respects, the financial condition and results of operations of Absolute Life Solutions , Inc.

Date: April 23, 2012

/s/ Avrohom Oratz

Avrohom Oratz

President and Chief
Executive Officer

(principal executive officer
and duly authorized officer)

EX-32.2

Exhibit 32.2

CERTIFICATION OF

CHIEF FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with the accompanying Quarterly Report on Form 10-Q of Absolute Life Solutions, Inc., for the quarter ending February 29, 2012, I, Joshua Yifat, Treasurer and Chief Financial Officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge and belief, that:

1.    Such Quarterly Report on Form 10-Q for the quarter  ending February 29, 2012, fully complies with the requirements of  Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.    The information contained in such Quarterly Report on Form 10-Q for the quarter  ending February 29, 2012, fairly represents in all material respects, the financial condition and results of operations of Absolute Life Solutions , Inc.

Date: April 23, 2012

/s/ Joshua Yifat

Joshua Yifat

Treasurer and Chief Financial Officer (principal  financial  officer and duly
authorized officer)

XML

PREFERRED STOCK

6 Months Ended

Feb. 29, 2012

Equity [Abstract]

Preferred Stock [Text Block]

4. PREFERRED STOCK

The total number of preferred shares authorized and that may be issued by the Company is 100,000,000 preferred shares with a par value of $0.00001. These preferred shares have no rights to voting, profit sharing or liquidation.

Of the total preferred shares authorized, pursuant to a Certificate of Designation dated July 22, 2010, 60,000 preferred shares have been designated as Series A 12.5% convertible preferred stock (the “Series A Preferred Stock”), with a par value of $0.00001. Effective April 7, 2011, an additional 25,000 preferred shares have been designated as Series B 12.5% convertible preferred stock (the “Series B Preferred Stock”), with a par value of $0.00001. In connection with the establishment of the Series B Preferred Stock, which is subordinate to the Series A Preferred Stock in respect of liquidation and redemption, the holders of 6,000 shares of Series A Preferred Stock agreed to exchange their Series A Preferred Stock for Series B Preferred Stock.  As a result, each exchanging Series A holder becomes a Series B holder and is entitled to receive an additional 50 Series B warrants exercisable at $4.00 for each share of preferred stock so exchanged. During the year ended August 31, 2011, the Company issued 34,450 shares of Series A  Preferred Stock, of which holders of 6,000 shares have agreed to exchange for Series B Preferred Stock and issued 2,850 of Series B Preferred Stock. In connection with the issuance of each Series A Preferred Stock, the Company issued 1,000 warrants (500 exercisable at $2.00 per share and 500 exercisable at $4 per share of common stock). In connection with the issuance of each share of Series B  Preferred Stock, the Company issued 1,050 warrants (500 exercisable at $2.00 per share and 550 exercisable at $4 per share of common stock).

The Series A convertible preferred shares were issued at $1,000 per share and each Series A convertible share is convertible into 1,000 shares of common stock at an initial conversion price of $1.00 per share. The Series A convertible preferred shares are convertible at the election of the holder. The conversion right is effective beginning on the earlier of 65 days after the initial issuance of the shares to the holder or the effective date of a registration statement filed by the Company covering the holder’s resale of the conversion shares. The earlier of the two dates will be the Conversion Date.

The holders of the shares of Series A Preferred Stock have the right to redeem the Series A Preferred Stock only upon existence of a Redemption Event. A Redemption Event is within control of the Company. A Redemption Event is described as:

(a) Failure of the Company to deliver certificates of conversion to the holders for any reason within 15 days after the Conversion Date and the holder has given 5 days’ notice thereof;

(b) A change in beneficial ownership of more than 50% of the common stock of the Company within a period of 40 trading days or involuntary change in a majority of the members of the Board of Directors of the Company within a period of 40 days; or

(c) Bankruptcy, reorganization, insolvency or liquidation proceedings which are not dismissed within 60 days.

If the holder redeems the Series A preferred shares, the Company will be obligated to pay the holder a redemption amount equal to the sum of (i) the stated value of the redeemed shares multiplied by 102%, if the redemption occurs within 5 years from the initial issuance; (ii) or by 100% if the redemption occurs after the 5 years. In addition, upon redemption, the Company must pay unpaid dividends through the date of such payment.

Dividends are payable at the rate of 12.5% per annum, in cash or in common stock, at the option of the Company. Dividends are payable semi-annually on the last day of June and December.

The Series A Preferred Stock does not have a maturity or mandatory redemption date, except upon certain limited acts of default. The Series A Preferred Stock does have a cash settlement provision.

The Series B convertible preferred shares were issued at $1,000 per share and each Series B convertible share is convertible into 1,000 shares of common stock at an initial conversion price of $1.00 per share. The Series B convertible preferred shares are convertible at the election of the holder. The conversion right is effective beginning on the earlier of 65 days after the initial issuance of the shares to the holder or the effective date of a registration statement filed by the Company covering the holder’s resale of the conversion shares. The earlier of the two dates will be the Conversion Date.

The holders of the shares of Series B Preferred Stock have the right to redeem the Series B Preferred Stock only upon existence of a Redemption Event. A Redemption Event is within control of the Company. A Redemption Event is described as:

(a) Failure of the Company to deliver certificates of conversion to the holders for any reason within 15 days after the Conversion Date and the holder has given 5 days’ notice thereof;

(b) A change in beneficial ownership of more than 50% of the common stock of the Company within a period of 40 trading days or involuntary change in a majority of the members of the Board of Directors of the Company within a period of 40 days; or

(c) Bankruptcy, reorganization, insolvency or liquidation proceedings which are not dismissed within 60 days.

If the holder redeems the Series B preferred shares, the Company will be obligated to pay the holder a redemption amount equal to the sum of (i) the stated value of the redeemed shares multiplied by 102%, if the redemption occurs within 5 years  from the  initial issuance;  (ii) or by  100% if  the redemption occurs after the 5 years. In addition, upon redemption, the Company must pay unpaid dividends through the date of such payment.

Dividends are payable at the rate of 12.5% per annum, in cash or in common  stock, at the option of the Company. Dividends are payable semi-annually on the last day of June and December.

The Series B Preferred Stock does not have a maturity or mandatory redemption date, except upon certain limited acts of default. The Series B Preferred Stock does have a cash settlement provision.

During the six months ended February 29, 2012, the issuance of 2,500 Series A Preferred Shares for aggregate proceeds of $2,500,000 with a contractual conversion price of $1.00 resulted in an effective conversion price lower than the fair market value of the Company’s Common Stock at each issuance after allocating the proceeds received to the preferred shares and the detachable warrants included with the preferred shares. Accordingly, the Company recorded deemed dividends in the aggregate amount of $932,643 attributable to the beneficial conversion feature.

XML

INVESTMENT IN LIFE SETTLEMENT CONTRACTS

6 Months Ended

Feb. 29, 2012

Investments, All Other Investments [Abstract]

Life Settlement Contracts, Disclosure [Text Block]

3. INVESTMENT IN LIFE SETTLEMENT CONTRACTS

The Company generally purchases life settlement contracts for long-term investment purposes and uses the fair value method to calculate its life settlement portfolio. The Company will also purchase life settlement contracts as a short-term investment for the purpose of reselling them to other investors.

When using fair value to measure assets and liabilities that are not actively trading, the Company follows the principles that clarify methods for measuring fair value when pricing these assets and liabilities. Further, the Company follows standards for the fair value option, which permits all entities to choose to measure eligible items at fair value at specified election dates. These standards state that a business entity shall report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date.

As of February 29, 2012 and August 31, 2011, the Company has the following investments in life settlement contracts at fair value:

	Number of Contracts		Estimated Fair Value		Face Value
August 31, 2011		39	$	92,708,076	$	274,750,633
February 29, 2012		38	$	86,270,563	$	269,742,932

The following table represents the remaining life expectancies for each of the first five succeeding years as of February 29, 2012 for life settlement contracts at fair value:

Number of Contracts	Life Expectancies	Face Value		Carrying Value
-	0-1 years	$	-	$	-
1	1-2 years		10,000,000		5,776,025
2	2-3 years		13,000,000		5,463,816
4	3-4 years		66,200,000		32,293,296
3	4-5 years		16,000,000		5,199,089
28	Thereafter		164,542,932		37,538,337
		$	269,742,932	$	86,270,563

The following table represents the remaining life expectancies for each of the first five succeeding years as of February 29, 2012 for life settlement contracts under the investment method:

Number of Contracts	Life Expectancies	Face Value		Carrying Value
-	0-1 years	$	-	$	-
-	1-2 years		-		-
-	2-3 years		-		-
-	3-4 years		-		-
3	4-5 years		8,000,000		1,104,126
8	Thereafter		42,500,000		2,280,216
		$	50,500,000	$	3,384,342

For the three months and six months ending February 29, 2012, the investments experienced an unrealized gain of $730,757 and an unrealized loss of $5,211,225 respectively and the Company paid policy premiums of $1,793,495 and $3,731,439 respectively. For the three months and six months ending February 28, 2011, the investments experienced an unrealized gain of $11,918,186 and $31,162,556 respectively and the Company paid policy premiums of $1,175,969 and $1,969,638 respectively. For the three months and six months ending February 29, 2012, the Company recognized a realized loss of $286,496. For the three months and six months ending February 28, 2011, the Company recognized a realized gain of $0 and $2,237,500 respectively.

The fair value of life settlement contracts is based on information available to the Company at period end. The Company considers the following factors in its fair value estimates: cost at date of purchase; recent purchases and sales of similar investments, financial standing of the issuer, changes in economic conditions affecting the issuer; standard actuarially developed mortality tables and industry life expectancy reports. The Company uses life expectancy reports that have been issued no later than 24 months from the ending date of the quarter being reported. Life expectancy reports are currently ordered from any two of the following life expectancy providers; AVS, 21^st Century, EMSI, ISC and Fasano. The Company considers that the underlying methodology of the life expectancy providers is an adequate gauge for calculating health status of the individual insured. Life expectancy data is used to simulate random possibilities of maturity, which form the basis for a statistical calculation that underlies our market valuations.

The fair value of the life settlement contracts are estimated using present value calculations. The following assumptions were used at February 29, 2012 and August 31, 2011:

	February 29, 2012	August 31, 2011
Dataset	VBT ALB Mortality Table	VBT ALB Mortality Table
Expected premium growth	5%	5%
Mortality rates	Standard life expectancy	Standard life expectancy
Discount rate	16%	14%

In the process of developing a benchmark from which to measure valuation, the Company uses the average redemption yield on the FINRA/Bloomberg High Yield US Corporate Bond Index as a starting point. This index measures the average yield on the highest risk debt obligations traded in the market and serves as a strong indicator of the yield that professional investors would require for similar types of assets. Traditionally, this index yields between 10 – 12%, therefore we added 250 - 350 basis points to the current index yield to account for the current uncharacteristically depressed high yield corporate bond market plus an additional 250 - 350 basis points for the highly illiquid and relatively new life settlements asset class. Our assumption is that short term US Treasuries typically trade in the 250 - 350 BP range. Given the current depressed market rates we have added 250 - 350 BP and will adjust this inversely to the short term Treasuries. As Treasuries rise the spread rate will diminish keeping the discount rate in line with the market. As the life settlement market continues to mature and the investment pools will become better managed the risk will diminish and the asset class will become more liquid. Current market players are better capitalized and understand the asset characteristics at a higher level. As such the discount rate should reflect a maturing market.

The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life settlement contracts and the Company’s estimate of the risk premium an investor in the policy would require. The Company believes that investors in alternative investments typically target yields averaging between 13 - 16% for investments of more than a 5 year duration. A 16% rate of return over a five year duration is a reasonable target for investments that are highly illiquid, relatively new and more volatile (i.e. life settlement contracts) than standard investments. In recent months, there have been a number of government investigations of several life settlement companies. These investigations, and subsequent SEC charges, in one instance, have caused a temporary dislocation in the life settlement market. Liquidity has tightened even further. In light of these factors, the Company believes the perceived risk or uncertainty over these assets has changed and therefore the risk premium an investor would require has changed, therefore management made a change in accounting estimate and adjusted its discount rate from 14% to 16% in the first quarter ending November 30, 2011, since management believes that a more conservative discount rate is appropriate due to the continued credit crunch in the market and in discussions with other investors in the life settlements market. The Company will continue to periodically assess the discount rate applied to its portfolio of life insurance policies which may result in future changes in fair value. The Company believes that this dislocation is temporary but is unable to predict how long it will take the market to return to a more traditional level. In the event that the dislocation and the market returns to a more traditional level, management will reevaluate the discount rate it uses in valuing its life settlement contracts.

The result of applying these assumptions and using Monte Carlo simulations for the quarter ended February 29, 2012 and year ended August 31, 2011 is as follows:

	February 29, 2012			August 31, 2011
Total Pool Benefit	$	269,742,932		$	274,750,633
Average predicted period until final pool maturity		8.16 yrs			9.03 yrs
Average simulated maturities over age 90		53	%		54	%
Average age at February 29, 2012 and August 31, 2011		82			82
Average age at maturity		91			91

The assumptions are, by their nature, inherently uncertain and the effect of changes in estimates may be significant. The fair value measurements used in estimating the present value calculations are derived from valuation techniques that include inputs for the asset that are not based on observable market data. The risks associated with the investments in life settlement contracts arise from the unknown remaining life expectancy, a change in credit worthiness of the policy issuer, funds needed to maintain the asset, and changes in the discount rate (See Note 7).

XML

CONDENSED BALANCE SHEETS (USD $)	Feb. 29, 2012	Aug. 31, 2011
ASSETS
Cash and cash equivalents	$ 2,053,670	$ 1,917,896
Accounts receivable	0	1,263,000
Insurance purchase escrow	0	128,750
Receivable under reverse repurchase agreement	0	3,368,593
Investment in life settlement contracts at investment method	3,384,342	0
Prepaid expenses	24,415	45,044
Total current assets	5,462,427	6,723,283
Equipment, net	78,106	90,082
Security deposit	56,688	56,688
Investment in life settlement contracts at fair value	86,270,563	92,708,076
TOTAL ASSETS	91,867,784	99,578,129
LIABILITIES
Accounts payable and accrued expenses	192,498	44,607
Due to provider	0	568,000
Income taxes payable	19,426	0
Total current liabilities	211,924	612,607
Deferred rent	46,002	42,148
Deferred income taxes	17,232,320	21,071,160
TOTAL LIABILITIES	17,490,246	21,725,915
STOCKHOLDERS' EQUITY
Common stock ($0.00001 par value; 500,000,000 authorized; 88,625,690 issued and outstanding) (August 31, 2011 - 85,424,597 issued and outstanding)	886	854
Additional paid in capital	103,439,392	96,773,677
Accumulated deficit	(29,062,740)	(18,922,317)
Total Stockholders' Equity	74,377,538	77,852,214
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	91,867,784	99,578,129
Series A Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred stock value	0	0
Series B Convertible Preferred Stock [Member]
STOCKHOLDERS' EQUITY
Preferred stock value	$ 0	$ 0

XML

NATURE AND CONTINUANCE OF OPERATIONS

6 Months Ended

Feb. 29, 2012

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Nature of Operations [Text Block]

1. NATURE AND CONTINUANCE OF OPERATIONS

Absolute Life Solutions, Inc. (the “Company”) was originally incorporated as Shimmer Gold, Inc. in the State of Nevada on September 7, 2006 and was in the business of the acquisition and exploration of mineral resources.

On May 21, 2010, the Company changed its name from Shimmer Gold, Inc. to Absolute Life Solutions, Inc. During the fiscal year ended August 31, 2010, the Company commenced operations as a specialty financial services company engaged in the business of purchasing life settlement contracts for long-term investment purposes.

The continued existence of the Company is dependent upon its ability to generate profit from its life settlement investments and to meet its obligations as they become due. If additional cash is needed, the Company intends to finance the future capital required to acquire life settlement contracts and continued operations from a combination of traditional debt and equity markets. However, there is no assurance that (a) traditional debt and equity markets may be accessible as required, or if so, on acceptable terms and, or (b) the demand for and selling prices of the Company’s products, may not be sufficient to meet cash flow requirements. The outcome of these matters cannot be predicted with certainty and therefore the Company may not be able to continue or expand operations as planned. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These unaudited condensed financial statements do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.

XML

SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Feb. 29, 2012

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies [Text Block]

2. SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited condensed financial statements as of February 29, 2012 and February 28, 2011 and for the three months and six months then ended have been prepared in accordance with the accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities and Exchange Commission (“SEC”) and on the same basis as the annual audited financial statements. The unaudited Balance Sheet as of February 29, 2012, Statements of Operations for the three months and six months ended February 29, 2012 and February 28, 2011, and Statements of Cash Flows for the six months ended February 29, 2012 and February 28, 2011, are unaudited, but include all adjustments, consisting only of normal recurring adjustments, which the Company considers necessary for a fair presentation of the financial position, operating results and cash flows for the period presented. The results for the three months and six months ended February 29, 2012 are not necessarily indicative of results to be expected for the year ending August 31, 2012 or for any future interim period. In addition, the balance sheet data at August 31, 2011 was derived from the audited financial statements but does not include all disclosures required by GAAP. The accompanying financial statements should be read in conjunction with the Company’s financial statements and notes thereto included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on December 14, 2011.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company's estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The most significant estimates with regard to these financial statements relate to deferred income tax amounts and rates and timing of the reversal of income tax differences, the fair value of financial instruments and the determination of the variables used in the calculation of the fair value of life settlement contracts.

Cash and Cash Equivalents

The Company considers all short term investments with an original maturity of three months or less to be cash equivalents. The Company maintains cash balances that may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation limits. The Company maintains its cash deposits with major financial institutions.

Receivable Under Reverse Repurchase Agreement

Transactions involving purchases of life settlement contracts under agreements to resell (reverse repurchase agreements or reverse repos) are accounted for as collateralized financings except where the Company does not have an agreement to sell the same or substantially the same life settlement contracts before maturity at a fixed or determinable price. The Company's policy is to obtain possession of collateral with a fair value equal to or in excess of the principal amount loaned under resale agreements.

At February 29, 2012 and August 31, 2011 the Company held zero and thirteen life settlement contracts as collateral in the amount of $0 and $3,368,593 respectively, which are reflected as a receivable under reverse repurchase agreement on the Balance Sheets. The counterparty did not exercise its rights under the repurchase agreements and upon expiration of the repurchase agreements, the Company recognized these assets as an investment in life settlement contract at investment method in the aggregate amount of $3,503,250.

The Company follows the provisions of ASC 860, Transfers and Servicing which requires an initial transfer of a financial asset and a repurchase financing that was entered into contemporaneously or in contemplation of the initial transfer to be evaluated as a linked transaction unless certain criteria are met, including that the transferred asset must be readily obtainable in the marketplace.

Life Settlement Contracts

ASC 325-30, Investments in Insurance Contracts allows an investor to elect to account for its investments in life settlement contracts using either the investment method or the fair value method. The election shall be made on an instrument-by instrument basis and is irrevocable. Under the investment method, an investor shall recognize the initial investment at the purchase price plus all initial direct costs. Continuing costs (policy premiums and direct external costs, if any) to keep the policy in force shall be capitalized. Under the fair value method, an investor shall recognize the initial investment at  the purchase  price.  In subsequent periods, the investor shall re-measure the investment at fair value in its entirety at each reporting period and shall recognize the change in fair value in the current period net of premiums paid. The Company primarily uses the fair value method to account for life settlement contracts. For those life settlement contracts held as a receivable under reverse repurchase agreement in the prior period, the Company elected to account for them under the investment method upon expiration of the repurchase agreement. The Company purchased these policies under a reverse repurchase agreement as a short-term investment for the purpose of reselling them to other investors.

Life settlement contracts are inherently long term investments. The individuals upon which the life insurance is underwritten are normally healthy with indications of continuing life spans in excess of 5 years. Accounting for the value of these policies using the fair value method provides a more accurate indication of the present value of these policies as it takes into account the net effect of holding the policy over an extended period during which the investment into the asset is increased, by virtue of continuing premium payments. When life settlement contracts are purchased for the purpose of short term gain, typically in a distressed sale, where the life settlement contracts are sold below market, the fair value method would give an inaccurate valuation as it would price in the distressed opportunity as if this was a normal occurrence in the market. Additionally, the concept of holding the policy for a period of less than one year would create a situation where the asset would be best recorded under the investment method.  

The fair value of the investment in life settlement contracts is evaluated at the end of each reporting period. Realized and unrealized changes in the fair value of the investment are recognized each reporting period in the statements of operations. The fair value is determined on a discounted cash flow basis that incorporates current life expectancy assumptions. The discount rate incorporates current information about market interest rates, the credit exposure to the insurance company that issued the life insurance policy and our estimate of the risk premium an investor in the policy would require.

For life settlement contracts accounted under the investment method, the Company will recognize the difference between the death benefits and the carrying value of the policy when the Company determines that settlement and ultimate collection is realizable and reasonably assured. Income from a transaction must meet both criteria in order to be recognized. Income is generally considered realized when cash is received for the sale of a product or performance of a service. Income generally becomes realizable when a promise to pay is received in exchange for the sale of a product or performance of a service. The promise to pay could be verbal (account receivable) or written (note receivable). Income is generally earned when a legally enforceable exchange takes place (e.g., consideration has been tendered and the buyer takes possession of the product or benefits from the performance of a service). The Company recognizes gains from these life settlement contracts that the company owns upon one of the two following events:

1) Receipt of death notice or verified obituary of insured.

2) Signed sale agreement and/or filing of change of ownership forms and funds transferred to escrow.

Financial Instruments

The fair value of certain of the Company's financial instruments, consisting of cash, accounts receivable, receivable under reverse repurchase agreement, investments in life settlement contracts at investment method, accounts payable, and accrued expenses are estimated to be equal to their carrying value due to the short-term nature of these instruments. Investments in life settlement contracts at fair value are classified as held-for-trading and measured at fair value, with the realized and unrealized changes in fair value recognized each reporting period in the statements of operations.

The Company measures the fair value of financial assets and liabilities based on the guidance of ASC 820, Fair Value Measurements and Disclosures which defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be used to measure fair value:

Level 1 — quoted prices in active markets for identical assets or liabilities

Level 2 — quoted prices for similar assets and liabilities in active markets or inputs that are observable

Level 3 — inputs that are unobservable (for example, cash flow modeling inputs based on assumptions)

It is management's opinion that the Company is not exposed to significant interest, currency and credit risks arising from these financial instruments. (See Note 7).

Deferred Rent Liability

The Company’s operating lease provides for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on the straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense.

Income Taxes

Deferred income taxes are provided for tax effects of temporary differences between the tax basis of asset and liabilities and their reported amounts in the financial statements. The Company uses the liability method to account for income taxes, which requires deferred taxes to be recorded at the statutory rate expected to be in effect when the taxes are paid. Valuation allowances are provided for a deferred tax asset when it is more likely than not that such asset will not be realized.

Management evaluates tax positions taken or expected to be taken in a tax return. The evaluation of a tax position includes a determination of whether a tax position should be recognized in the financial statements, and such a position should only be recognized if the Company determines that it is more likely than not that the tax position will be sustained upon examination by the tax authorities, based upon  the technical merits of the position. For those tax positions that should be recognized, the measurement of a tax position is determined as being the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement.

Earnings (Loss) per Share

Basic earnings (loss) per share is calculated using the weighted average number of shares of common stock outstanding during the period. Included in basic loss per share calculations are the effects of 6,000,000 warrants exercisable at $.01. Diluted earnings per share reflect the potential dilution that could occur if potentially dilutive securities were exercised or converted to common stock.  The dilutive effect of options and warrants and their equivalent is computed by application of the treasury stock method and the effect of convertible securities by the “if converted” method. For the three months and six months ended February 29, 2012, 26,650,000 and 27,092,500 warrants with an exercise price of $2.00 and $4.00 respectively, and 53,300 Series A and Series B preferred shares, convertible into 53,300,000 common shares are not included in diluted earnings per share since their effect would be anti-dilutive. For the three months and six months ended February 28, 2011, 16,350,000 warrants with an exercise price of $2.00 and 32,700,000 Series A preferred shares, convertible into 32,700,000 common shares are not included in diluted earnings per share since their effect would be anti-dilutive.

Stock-Based Compensation

The Company accounts for stock based compensation arrangements using a fair value method and records such expense on a straight-line basis over the vesting period.

As of February 29, 2012, the Company has not granted any stock options.

Recent Accounting Pronouncements

The FASB has issued Accounting Standards Update (ASU) No. 2010-15, Financial Services—Insurance (Topic 944): How Investments Held through Separate Accounts Affect an Insurer’s Consolidation Analysis of Those Investments.  This ASU codifies the consensus reached in EITF Issue No. 09-B, "Consideration of an Insurer's Accounting for Majority-Owned Investments When the Ownership Is through a Separate Account." The amendments clarify that an insurance entity generally should not consider any separate account interests held for the benefit of policy holders in an investment to be the insurer's interests and should not combine those interests with its general account interest in the same investment when assessing the investment for consolidation. The general guidance does not apply in instances where the separate account interests are held for the benefit of a related party policy holder as defined in the Variable Interest Entities Subsections of Codification Topic 810, Consolidation,  Subtopic 810-10, as those Subsections require the consideration of related parties. ASU 2010-15 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2010. Early adoption is permitted. The adoption of this standard did not have a material impact on the Company’s financial position and results of operations.

Other pronouncements issued by the FASB or other authoritative accounting standards groups with future effective dates are either not applicable or are not expected to be significant to the financial statements of the Company.

XML

CONDENSED BALANCE SHEETS [Parenthetical] (USD $)	6 Months Ended	12 Months Ended
	Feb. 29, 2012	Aug. 31, 2011
Preferred stock, par value (in dollars per share)	0.00001	0.00001
Preferred stock, shares authorized	100,000,000	100,000,000
Common stock, par value (in dollars per share)	0.00001	0.00001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	88,625,690	85,424,597
Common stock, shares outstanding	88,625,690	85,424,597
Series A Convertible Preferred Stock [Member]
Preferred stock, shares designated	60,000	60,000
Preferred stock, dividend rate, percentage	12.50%	12.50%
Preferred stock, shares issued	44,450	41,950
Preferred stock, shares outstanding	44,450	41,950
Series B Convertible Preferred Stock [Member]
Preferred stock, shares designated	25,000	25,000
Preferred stock, dividend rate, percentage	12.50%	12.50%
Preferred stock, shares issued	8,850	8,850
Preferred stock, shares outstanding	8,850	8,850

XML

DOCUMENT AND ENTITY INFORMATION	6 Months Ended
	Feb. 29, 2012	Apr. 18, 2012
Entity Registrant Name	ABSOLUTE LIFE SOLUTIONS, INC.
Entity Central Index Key	0001421538
Current Fiscal Year End Date	--08-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	also
Entity Common Stock, Shares Outstanding		88,625,690
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Feb. 29, 2012
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2012

XML

CONDENSED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Feb. 29, 2012	Feb. 28, 2011	Feb. 29, 2012	Feb. 28, 2011
Sales, general and administrative expenses	$ (509,630)	$ (708,814)	$ (884,773)	$ (1,778,661)
Other income
Realized gain on life settlement contracts held under investment method	0	0	319,843	0
Change in fair value of life settlement contracts net of premiums paid	(1,349,234)	10,742,217	(9,229,160)	31,430,418
Income (loss) before income taxes	(1,858,864)	10,033,403	(9,794,090)	29,651,757
Income tax benefit (provision)	272,581	(5,251,490)	3,819,414	(13,825,451)
Net income (loss)	(1,586,283)	4,781,913	(5,974,676)	15,826,306
Deemed dividend on issuance of Series A and Series B Preferred Stock	(932,643)	(5,950,000)	(932,643)	(19,200,000)
Dividend on Convertible Preferred Stock	(3,233,104)	(2,286,018)	(3,233,104)	(2,286,018)
Net income (loss) applicable to common shareholders	$ (5,752,030)	$ (3,454,105)	$ (10,140,423)	$ (5,659,712)
Basic earnings (loss) per common share (in dollars per share)	$ (0.06)	$ (0.04)	$ (0.11)	$ (0.06)
Diluted earnings (loss) per common share (in dollars per share)	$ (0.06)	$ (0.04)	$ (0.11)	$ (0.06)
Basic weighted average shares outstanding (in shares)	93,500,031	88,243,904	92,462,314	87,827,881
Diluted weighted average shares outstanding (in shares)	93,500,031	88,243,904	92,462,314	87,827,881

XML

FAIR VALUE OF FINANCIAL INSTRUMENTS

6 Months Ended

Feb. 29, 2012

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

7. FAIR VALUE OF FINANCIAL INSTRUMENTS

The following table provides an analysis of Level 3 financial instruments that are re-measured subsequent to initial recognition at fair value. The Company determined that its investment in life settlements at fair value is a Level 3 financial instrument and that it has no Level 1 or Level 2 financial instruments:

Reconciliation of Level 3 fair value measurements of financial assets on a recurring basis using unobservable inputs as of February 29, 2012 and August 31, 2011:

Unquoted Life Settlement Contracts:	February 29, 2012			August 31, 2011
Beginning balance	$	92,708,076		$	12,313,897
Transfers in:
Purchases of life settlement contracts		-			29,791,549
Change in fair value of life settlement contracts		(5,497,721	)		53,102,630
Transfers out:
Proceeds from sale of life settlement contract		(939,792	)		-
Proceeds from maturity of life settlement contract		-			(2,500,000	)
Ending balance	$	86,270,563		$	92,708,076

The extent to which the fair value could reasonably vary in the near term has been quantified by evaluating the effect of changes in significant underlying assumptions used to estimate the amount. If the discount factors were increased or decreased by 2% while all other variables are held constant, the carrying value of the investment in life settlement policies would be:

	Discount Rate as of February 29, 2012				Discount rate as of August 31, 2011
	+ 2%		(2%)		+ 2%		(2%)
Investment in Life Settlement Contracts	$	79,922,024	$	93,453,519	$	85,215,603	$	101,271,273

The Company utilizes the MAPS system for valuations. MAPS is a generally accepted third party pricing system utilized by funds and investors engaged in the purchase and sale of life settlements.

Life expectancy reports are generated by third party medical underwriting firms, such as AVS, 21 ^st Century, EMSI and Fasano. These firms review medical data for an individual and grade using a series of debits and credits. The resulting values are used to generate a life expectancy value. The MAPS system utilizes this life expectancy data to calibrate underlying mortality curves generated for each individual case.

MAPS utilizes the appendixes to the VBT2008 report as a base for mortality projections. This chart established 25 unique values corresponding to 25 statistical values indicative of the next 25 years of a persons life. The value is the statistical probability that the individual will meet an untimely end in that given year. When a life expectancy provider produces a report, it indicates a value at which point a certain individual will achieve a 50% chance, statistically, of dying. This is calculated by randomly making 1000 simulations and calculating an exact point of death for each simulation. The point at which the cumulative deaths equal 500 is the median point or the life expectancy.

In order to calibrate this curve, a multiplier is formulated to cause the median mark to equal the life expectancy value provided by the life expectancy provider. For every case, 1000 simulations are run, each simulation resulting in a unique death month. For example, if a life expectancy equals 50 months, the underlying data would show 500 deaths prior to the 50th month and 500 deaths after the 50th month.

The MAPS system takes the results of the modified life expectancy curve and applies it to the premium and death benefit projections stream. For the 500 deaths prior to the 50th month, utilizing our previous example, it would apply the percentage of the simulated runs that died in each 12 month period to the death benefit and premium schedules to form estimated cash flows. The net present value, using a discount rate defined by the user, of the streams of values created by this method form the indicated value of the policy.

XML

COMMITMENTS

6 Months Ended

Feb. 29, 2012

Commitments and Contingencies Disclosure [Abstract]

Commitments Disclosure [Text Block]

6. COMMITMENTS

 Life insurance premiums are future payments required to keep the insurance policies, comprising the Company’s investment in life settlement contracts, intact. At February 29, 2012, the premiums to be paid for each of the five succeeding fiscal years ending August 31for investment in life settlement contracts at fair value are as follows:

Year	Amount
2012	$	8,810,109
2013		17,581,956
2014		17,543,693
2015		17,543,693
2016		17,543,693
Thereafter		196,759,667
	$	275,782,811

At February 29, 2012, the premiums to be paid for each of the five succeeding fiscal years ending August 31for investment in life settlement contracts at investment method are as follows:

Year	Amount
2012	$	1,388,486
2013		2,776,971
2014		2,776,971
2015		2,776,971
2016		2,776,971
Thereafter		35,246,528
	$	47,742,898

XML

SUBSEQUENT EVENTS

6 Months Ended

Feb. 29, 2012

Subsequent Events [Abstract]

Subsequent Events [Text Block]

10. SUBSEQUENT EVENTS

The Company evaluates events that have occurred after the balance sheet date through the date the financial statements were publicly available. Based upon the evaluation, the Company did not identify any other recognized or non-recognized subsequent events that would have required adjustment or disclosure in the financial statements .

XML

INCOME TAXES

6 Months Ended

Feb. 29, 2012

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

8. INCOME TAXES

Income tax (benefit) expense consists of the following components at February 29, 2012 and 2011:

	2012			2011
Current tax expense	$	19,426		$	63,213
Deferred tax (benefit) expense		(3,838,840	)		13,762,238
Total income tax (benefit) expense	$	(3,819,414	)	$	13,825,451

The Company calculates its interim tax provision in accordance with the provisions of ASC 740-270, Income Taxes; Interim Reporting . For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items we report separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur.

In computing the annual estimated effective tax rate the Company makes certain estimates and judgments, such as estimated annual taxable income or loss, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. These estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. The difference between the statutory rate of 35% and the effective rate of 40% is primarily attributable to the affect of state and local taxes.

As of February 29, 2012, the Company has filed income tax returns through the fiscal 2009 tax year. The Company is required to file income tax returns in the United States (federal) and in New York State and City. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The evaluation was performed for the August 31, 2007 – August 31, 2011 tax years, which remain subject to examination. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position.

The Company’s policy for recording interest and penalties associated with audits is to record such expense as a component of income tax expense. There are no significant amounts accrued for penalties or interest as of or during the three months and six months ended February 29, 2012 and February 28, 2011. Management is currently unaware of any issues under review that could result in significant payments, accruals or material deviations from its position.

XML

RELATED PARTY TRANSACTIONS

6 Months Ended

Feb. 29, 2012

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

9. RELATED PARTY TRANSACTIONS

During the quarter ended February 29, 2012, the Company received short-term loans from a shareholder of $775,000. The loans were at a rate of 8% per annum with a maturity date ending on or before February 29, 2012. The Company paid the loans in full as of February 29, 2012. Interest expense of $2,800 is included in sales, general and administrative expenses on the Condensed Statements of Operations.

XML

CONDENSED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Feb. 29, 2012	Feb. 28, 2011
OPERATING ACTIVITIES
Net income (loss)	$ (5,974,676)	$ 15,826,306
Adjustments to reconcile net income (loss) to net cash used in operations
Issuances of common stock for services	0	850,530
Unrealized changes in fair value of life settlement contracts	5,211,225	(31,162,556)
Realized gain on maturity of life settlement contract	0	(2,237,500)
Realized loss on sale of life settlement contract at fair value	286,496	0
Realized gain on sale of life settlement contracts at investment method	(319,843)	0
Depreciation	11,976	11,978
Deferred rent	3,854	0
Deferred income taxes	(3,838,840)	13,762,238
Changes in operating assets and liabilities
Accounts receivable	1,263,000	0
Insurance purchase escrow	128,750	(450,000)
Prepaid expenses	20,629	(13,544)
Accounts payable and accrued expenses	147,891	(317,454)
Income taxes payable	19,426	63,213
Due to provider	(568,000)	0
Net cash used in operating activities	(3,608,112)	(3,666,789)
INVESTING ACTIVITIES
Purchases of life settlement contracts	0	(19,118,000)
Proceeds from maturity of life settlement contract	0	2,500,000
Proceeds from sale of life settlement contract at fair value	939,792	0
Proceeds from sale of life settlement contracts at investment method	897,234	0
Investment in life settlement contracts at investment method	(458,473)	0
Investment in reverse repurchase agreement	(134,667)	0
Net cash provided by (used in) investing activities	1,243,886	(16,618,000)
FINANCING ACTIVITIES
Proceeds from issuance of preferred stock	2,500,000	19,200,000
Proceeds from shareholder loan	775,000	0
Payment of shareholder loan	(775,000)	0
Net cash provided by financing activities	2,500,000	19,200,000
Change in cash and cash equivalents	135,774	(1,084,789)
Cash and cash equivalents, beginning	1,917,896
Cash and cash equivalents, ending	2,053,670	2,413,736
Supplemental disclosure of non-cash investing activity:
Transfer of receivable under reverse repurchase to investment in life settlement contracts at investment method	$ 3,503,260	$ 0

XML

COMMON STOCK

6 Months Ended

Feb. 29, 2012

Stockholders Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

5. COMMON STOCK

A.   The Company did not issue additional common stock during the six months ended February 29, 2012.

On December 22, 2011, the Board of Directors authorized that the Company issue 3,201,093 shares of common stock as payment of the 12.5% dividend for December 31, 2011 on the Series A Preferred Stock and Series B Preferred Stock.

B.    Warrant transactions are summarized as follows:

	Number of  warrants		Weighted average exercise price		Weighted average life remaining (in years)
Balance as at August 31, 2011
Issued		57,242,500		2.69		4.33 years
Additions as of February 29, 2012
Issued		2,500,000		-		5.00 years
Balance as at February 29, 2012		59,742,500		2.71		3.80 years

As of February 29, 2012, there were 59,742,500 warrants outstanding and exercisable with expiration dates commencing June 2015 through February 2017. If a Registration Statement is not effective at the time of exercise, the holder may elect a “cashless exercise” resulting in no additional proceeds from the warrant exercise received by the Company.

Except as set forth, the warrants do not permit net cash settlement.